Syndax Pharmaceuticals Valuation
| SNDX Stock | USD 14.10 0.98 7.47% |
At this time, the company appears to be overvalued. Syndax Pharmaceuticals has a current Real Value of $11.58 per share. The regular price of the company is $14.1. Our model measures the value of Syndax Pharmaceuticals from inspecting the company fundamentals such as Current Valuation of 891.47 M, shares owned by insiders of 1.29 %, and Return On Equity of -0.76 as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Syndax Pharmaceuticals' valuation include:
Price Book 3.9172 | Enterprise Value | Enterprise Value Ebitda (105.26) | Price Sales 47.6622 | Enterprise Value Revenue 37.6464 |
Overvalued
Today
Please note that Syndax Pharmaceuticals' price fluctuation is somewhat reliable at this time. Calculation of the real value of Syndax Pharmaceuticals is based on 3 months time horizon. Increasing Syndax Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Syndax Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Syndax Stock. However, Syndax Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 14.1 | Real 11.58 | Target 36.46 | Hype 13.12 | Naive 13.15 |
The intrinsic value of Syndax Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Syndax Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Syndax Pharmaceuticals helps investors to forecast how Syndax stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Syndax Pharmaceuticals more accurately as focusing exclusively on Syndax Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Syndax Pharmaceuticals' intrinsic value based on its ongoing forecasts of Syndax Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Syndax Pharmaceuticals' closest peers.
Syndax Pharmaceuticals Cash |
|
Syndax Valuation Trend
Analysing the historical paterns of Syndax Pharmaceuticals' enterprise value and its market capitalization is a good way to estimate and gauge the value of Syndax Pharmaceuticals over time and is usually enough for investors to make rational market timing decisions.
Syndax Pharmaceuticals Total Value Analysis
Syndax Pharmaceuticals is at this time forecasted to have valuation of 891.47 M with market capitalization of 1.13 B, debt of 12.12 M, and cash on hands of 350.71 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Syndax Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
891.47 M | 1.13 B | 12.12 M | 350.71 M |
Syndax Pharmaceuticals Investor Information
About 99.0% of the company shares are owned by institutional investors. The book value of Syndax Pharmaceuticals was at this time reported as 3.36. The company has Price/Earnings (P/E) ratio of 126.11. Syndax Pharmaceuticals recorded a loss per share of 3.72. The entity had not issued any dividends in recent years. Based on the key indicators related to Syndax Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Syndax Pharmaceuticals is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April.Syndax Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Syndax Pharmaceuticals has an asset utilization ratio of 3.27 percent. This suggests that the Company is making $0.0327 for each dollar of assets. An increasing asset utilization means that Syndax Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Syndax Pharmaceuticals Ownership Allocation
The majority of Syndax Pharmaceuticals outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Syndax Pharmaceuticals to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Syndax Pharmaceuticals. Please pay attention to any change in the institutional holdings of Syndax Pharmaceuticals as this could imply that something significant has changed or is about to change at the company.Syndax Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 23.68 M. Net Loss for the year was (318.76 M) with loss before overhead, payroll, taxes, and interest of (218.79 M).About Syndax Pharmaceuticals Valuation
Our relative valuation model uses a comparative analysis of Syndax Pharmaceuticals. We calculate exposure to Syndax Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Syndax Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 22.9 M | 17.1 M | |
| Pretax Profit Margin | (12.11) | (12.72) | |
| Operating Profit Margin | (12.91) | (13.56) | |
| Net Loss | (12.11) | (12.72) | |
| Gross Profit Margin | 1.11 | 1.08 |
Syndax Pharmaceuticals Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 85.4 M |
Syndax Pharmaceuticals Current Valuation Indicators
Valuation refers to the process of determining the present value of Syndax Pharmaceuticals and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Syndax we look at many different elements of the entity such as Syndax's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Syndax Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Syndax Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Syndax Pharmaceuticals' worth.Additional Tools for Syndax Stock Analysis
When running Syndax Pharmaceuticals' price analysis, check to measure Syndax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syndax Pharmaceuticals is operating at the current time. Most of Syndax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syndax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syndax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syndax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.